Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013, Article ID 382523, 5 pages
http://dx.doi.org/10.1155/2013/382523
Clinical Study

Plasma Clusterin Concentrations May Predict Resistance to Intravenous Immunoglobulin in Patients with Kawasaki Disease

Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, 123 Ta-Pei Road, Niao-Sung, Kaohsiung 833, Taiwan

Received 2 May 2013; Accepted 5 June 2013

Academic Editors: G. P. Chrousos, S. Cuzzocrea, and L. He

Copyright © 2013 Mei-Chen Ou-Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Burns, E. V. Capparelli, J. A. Brown, J. W. Newburger, and M. P. Glode, “Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group,” Pediatric Infectious Disease Journal, vol. 17, no. 12, pp. 1144–1148, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. Burns and M. P. Glodé, “Kawasaki syndrome,” The Lancet, vol. 364, no. 9433, pp. 533–544, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. C. Burns, “The riddle of Kawasaki disease,” New England Journal of Medicine, vol. 356, no. 7, pp. 659–661, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. Wallace, J. W. French, S. J. Kahn, and D. D. Sherry, “Initial intravenous gammaglobulin treatment failure in Kawasaki disease,” Pediatrics, vol. 105, no. 6, p. E78, 2000. View at Google Scholar · View at Scopus
  5. K. Durongpisitkul, J. Soongswang, D. Laohaprasitiporn, A. Nana, C. Prachuabmoh, and C. Kangkagate, “Immunoglobulin failure and retreatment in Kawasaki disease,” Pediatric Cardiology, vol. 24, no. 2, pp. 145–148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Y. Ban, K. L. Yoon, S. K. Kim, S. Kang, and J.-H. Chung, “Promoter polymorphism (rs3755724, −55C/T) of tissue inhibitor of metalloproteinase 4 (TIMP4) as a risk factor for Kawasaki disease with coronary artery lesions in a Korean population,” Pediatric Cardiology, vol. 30, no. 3, pp. 331–335, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. H. Biezeveld, I. M. Kuipers, J. Geissler et al., “Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease,” The Lancet, vol. 361, no. 9365, pp. 1268–1270, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Kim, W. Choi, C.-W. Woo et al., “Predictive risk factors for coronary artery abnormalities in Kawasaki disease,” European Journal of Pediatrics, vol. 166, no. 5, pp. 421–425, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Nishimura, M. Zaitsu, M. Hara et al., “A polymorphism in the promoter of the CD14 gene (CD14/−159) is associated with the development of coronary artery lesions in patients with kawasaki disease,” Journal of Pediatrics, vol. 143, no. 3, pp. 357–362, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Nofech-Mozes and B.-Z. Garty, “Thrombocytopenia in Kawasaki disease: a risk factor for the development of coronary artery aneurysms,” Pediatric Hematology and Oncology, vol. 20, no. 8, pp. 597–601, 2003. View at Google Scholar · View at Scopus
  11. T. Ohno, H. Igarashi, K. Inoue, K. Akazawa, K. Joho, and T. Hara, “Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease,” European Journal of Pediatrics, vol. 159, no. 6, pp. 424–429, 2000. View at Google Scholar · View at Scopus
  12. E. Salo, E. Pesonen, and J. Viikari, “Serum cholesterol levels during and after Kawasaki disease,” Journal of Pediatrics, vol. 119, no. 4, pp. 557–561, 1991. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Song, Y. Yeo, K. Ha et al., “Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age,” European Journal of Pediatrics, vol. 168, no. 11, pp. 1315–1321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. H.-R. Yu, H.-C. Kuo, E.-Y. Huang et al., “Plasma clusterin levels in predicting the occurrence of coronary artery lesions in patients with kawasaki disease,” Pediatric Cardiology, vol. 31, no. 8, pp. 1151–1156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. H.-R. Yu, H.-C. Kuo, J.-M. Sheen et al., “A unique plasma proteomic profiling with imbalanced fibrinogen cascade in patients with Kawasaki disease,” Pediatric Allergy and Immunology, vol. 20, no. 7, pp. 699–707, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. H. C. Kuo, C. L. Wang, C. D. Liang et al., “Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease,” Pediatric Allergy and Immunology, vol. 20, pp. 266–272, 2009. View at Publisher · View at Google Scholar
  17. H.-C. Kuo, K. D. Yang, C.-D. Liang et al., “The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease,” Pediatric Allergy and Immunology, vol. 18, no. 4, pp. 354–359, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Fury, A. H. Tremoulet, V. E. Watson et al., “Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance,” Human Immunology, vol. 71, no. 9, pp. 865–873, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Suzuki, T. Suenaga, T. Takeuchi, S. Shibuta, and N. Yoshikawa, “Marker of T-cell activation is elevated in refractory Kawasaki disease,” Pediatrics International, vol. 52, no. 5, pp. 785–789, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. H. Tremoulet, B. M. Best, S. Song et al., “Resistance to intravenous immunoglobulin in children with Kawasaki disease,” Journal of Pediatrics, vol. 153, no. 1, pp. 117–e3, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Rigante, P. Valentini, D. Rizzo et al., “Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome,” Rheumatology International, vol. 30, no. 6, pp. 841–846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. J. W. Newburger, L. A. Sleeper, B. W. McCrindle et al., “Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki Disease,” New England Journal of Medicine, vol. 356, no. 7, pp. 663–675, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. van Dijk, R. A. Vermond, P. A. J. Krijnen et al., “Intravenous clusterin administration reduces myocardial infarct size in rats,” European Journal of Clinical Investigation, vol. 40, no. 10, pp. 893–902, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. ter Weeme, A. B. A. Vonk, K. Kupreishvili et al., “Activated complement is more extensively present in diseased aortic valves than naturally occurring complement inhibitors: a sign of ongoing inflammation,” European Journal of Clinical Investigation, vol. 40, no. 1, pp. 4–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. V. Poulakou, K. I. Paraskevas, M. R. Wilson et al., “Apolipoprotein J and leptin levels in patients with coronary heart disease,” In Vivo, vol. 22, no. 4, pp. 537–542, 2008. View at Google Scholar · View at Scopus
  26. I. P. Trougakos, M. Poulakou, M. Stathatos, A. Chalikia, A. Melidonis, and E. S. Gonos, “Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction,” Experimental Gerontology, vol. 37, no. 10-11, pp. 1175–1187, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Kujiraoka, H. Hattori, Y. Miwa et al., “Serum apolipoprotein J in health, coronary heart disease and type 2 diabetes mellitus,” Journal of Atherosclerosis and Thrombosis, vol. 13, no. 6, pp. 314–322, 2006. View at Google Scholar · View at Scopus
  28. D. K. Swertfeger, D. P. Witte, W. D. Stuart, H. A. Rockman, and J. A. K. Harmony, “Apolipoprotein J/clusterin induction in myocarditis. A localized response gene to myocardial injury,” American Journal of Pathology, vol. 148, no. 6, pp. 1971–1983, 1996. View at Google Scholar · View at Scopus
  29. P. A. J. Krijnen, S. A. G. M. Cillessen, R. Manoe et al., “Clusterin: a protective mediator for ischemic cardiomyocytes?” American Journal of Physiology—Heart and Circulatory Physiology, vol. 289, no. 5, pp. H2193–H2202, 2005. View at Publisher · View at Google Scholar · View at Scopus